# InMode Ltd. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/InMode Ltd.). ## Overview InMode Ltd. develops, manufactures, and markets minimally invasive medical devices built around radiofrequency technology. Its systems are used across aesthetic and specialty medical procedures, with customers in plastic surgery, dermatology, gynecology, otolaryngology, and ophthalmology markets in the United States, Israel, Europe, and other international regions. ## Products & services • Radiofrequency-based minimally invasive medical devices • Aesthetic treatment platforms for plastic surgery and dermatology • Gynecology procedure systems • Otolaryngology and ophthalmology procedure devices • Device accessories and consumables tied to procedures - **Aesthetic procedure platforms** (45%) — RF-based devices used in plastic surgery and aesthetic medicine procedures. - **Dermatology systems** (25%) — Energy-based devices used by dermatology practices for skin and body treatments. - **Gynecology devices** (15%) — Systems and tools used in minimally invasive gynecological procedures. - **ENT and ophthalmology devices** (10%) — Specialty medical devices used in otolaryngology and ophthalmology applications. - **Accessories and consumables** (5%) — Procedure-related handpieces, disposables, and supporting items sold with devices. - Radiofrequency-based minimally invasive medical devices - Aesthetic treatment platforms for plastic surgery and dermatology - Gynecology procedure systems - Otolaryngology and ophthalmology procedure devices - Device accessories and consumables tied to procedures ## Customers InMode sells primarily to medical professionals and clinics that perform elective or specialty procedures using energy-based technology. The core users are plastic surgeons, dermatologists, gynecologists, ENT specialists, and ophthalmologists, who buy the systems to broaden procedure offerings and improve treatment workflows. Purchases are typically made by outpatient practices, clinics, and medical groups that invest in capital equipment tied to procedure volume and patient demand. - **Plastic surgery practices** (primary) — Buy RF platforms for aesthetic and minimally invasive body procedures. - **Dermatology clinics** (primary) — Buy devices for skin tightening, contouring, and related treatments. - **Gynecology practices** (secondary) — Buy procedure systems for minimally invasive women's health applications. - **ENT and ophthalmology practices** (secondary) — Buy specialty devices for selected surgical and procedural uses. - **Medical groups and outpatient centers** (secondary) — Buy equipment to support procedure throughput and service expansion. - Plastic surgeons buying devices for aesthetic and body-contouring procedures - Dermatology practices using RF platforms for skin and contour treatments - Gynecology specialists needing minimally invasive procedure systems - ENT and ophthalmology clinics using specialty RF applications - Outpatient medical groups seeking capital equipment for procedure volume ## Geography InMode is a global business with development and operating roots in Israel and commercial exposure across the United States, Europe, and other international markets. The company’s reports specifically note that the U.S. contributed meaningfully to recent growth, while management continues to build out sales and management coverage in North America and Europe. Its geographic mix matters because demand for elective medical procedures, reimbursement norms, and distributor coverage can vary significantly by region. - **Israel** (0%) — Operating base and headquarters, not a disclosed revenue share - **United States** (0%) — Major market mentioned in management commentary, but no share disclosed - **Europe** (0%) — Commercial region mentioned in management commentary, but no share disclosed - **International** (0%) — Other markets referenced in company description, no disclosed breakdown - Israel is the company's operating and development base - The United States is a major commercial market - Europe is an important sales region for aesthetic devices - International sales matter for growth outside the U.S. - Regional sales force coverage affects market penetration ## Strategy InMode’s strategy centers on expanding adoption of its RF platforms across aesthetic and specialty medical practices while strengthening commercial execution in North America and Europe. The company also emphasizes capital allocation discipline, including share repurchases, while continuing to invest in sales and management coverage that supports procedure adoption and recurring customer relationships. - **Commercial expansion in North America** (short-term) — The U.S. is a key market and recent commentary highlighted its contribution to growth. - **European market execution** (short-term) — Europe is a meaningful region for aesthetic devices and requires local commercial coverage. - **Broaden procedure adoption** (medium-term) — More procedure use increases installed-base value and repeat commercial opportunity. - **Capital allocation discipline** (short-term) — Repurchases can return cash when operations generate surplus liquidity. - Expand adoption of RF platforms across aesthetic specialties - Strengthen sales and management coverage in North America - Build operating presence in Europe and other international markets - Use capital returns as a deployment of excess cash - Support broader procedure adoption through product breadth ## Risks InMode is exposed to discretionary demand for aesthetic and elective procedures, which can soften when macroeconomic conditions weaken or patient spending is deferred. The company also faces execution risk in geographically dispersed sales organizations, competitive pressure in energy-based medical devices, and event risk tied to its ongoing regional exposure in Israel. Product development, regulatory requirements, and reliance on physician adoption also shape the risk profile. - **Discretionary demand for aesthetic procedures** [high] — Customers can delay elective purchases and procedure utilization when economic conditions weaken. - **Sales force execution in key regions** [medium] — Revenue depends on effective physician coverage, training, and local account development. - **Geopolitical exposure in Israel** [medium] — The company is headquartered and operates from Israel, so conflict can affect operations and sentiment. - **Competitive pressure in RF medical devices** [medium] — Alternative energy-based platforms and new entrants can affect share and pricing. - Elective procedure demand can be delayed in weaker macro conditions - Sales execution risk in North America and Europe affects growth - Competition in energy-based devices can pressure adoption and pricing - Regional conflict in Israel can affect operations and logistics - Regulatory and clinical acceptance are essential for device adoption ## Accounting InMode’s reported results are affected by non-GAAP adjustments that exclude share-based compensation and certain special committee expenses, which can make operating performance look different from GAAP results. Revenue timing is important because device sales and related procedure-demand trends can vary by quarter, and management commentary indicates changing demand conditions across regions. Investors should also watch for valuation allowance changes, stock repurchase accounting, and any estimates tied to tax positions or contingent costs. - **Non-GAAP exclusions** — Affects operating margin and EPS presentation - **Revenue timing and quarterly seasonality** — Impacts quarterly growth rates and margin trends - **Income tax valuation allowance** — Can materially affect tax expense and net income - **Share repurchase accounting** — Affects diluted EPS and equity balances - Non-GAAP adjustments exclude share-based compensation and committee expenses - Quarterly revenue can shift with procedure demand and sales timing - Tax valuation allowance changes can affect reported tax expense - Share repurchases affect share count and per-share results - Regional demand swings can increase quarter-to-quarter comparability noise --- *Last updated: 2026-09-28T12:04:04.668816+00:00*